Live Breaking News & Updates on Over Five Years After Completing

Stay updated with breaking news from Over five years after completing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER. ....

Puerto Rico , United States , Michael Strapazon , Jessica Akopyan , Amgen Medinfo , Kyowa Kirin Co Ltd , Beigene Ltd , Exchange Commission , Therapeutics Inc , European Union , Teneobio Inc , Studies Showed Sustained Reduction , Combined Studies Evaluated Safety , More Than , Over Five Years After Completing , Longest Studied , Risk Open Label Extension , Eastern Europe , Cardiovascular Open Label Extension , Dow Jones Industrial Average , Best Workplaces , Great Place , Primary Hyperlipidemia , Cardiovascular Outcomes Trial , Pediatric Patients , Prescribing Information ,